Onco-Innovations and Nucro-Technics Initiate Preclinical PNKP Program

Vancouver-based Onco-Innovations Limited has partnered with Toronto's Nucro-Technics Inc. to advance its preclinical program for the Polynucleotide Kinase Phosphatase (PNKP) inhibitor. The collaboration focuses on analytical development under Onco's Investigational New Drug program. This phase aims to develop and validate analyzation methods for the exclusive PNKP technology, crucial for tracking drug processing within the body.

Nucro-Technics employs liquid chromatography-mass spectrometry (LC-MS) to measure PNKP in various biological systems. This dual capability provides data on drug stability and metabolism, supporting the novel formulation approach of Onco. Upon validation, these methods will form the basis for future studies, including toxicology and pharmacokinetics.

According to Onco's CEO, Thomas O'Shaughnessy, these validated tools will support regulatory submissions and deepen understanding of PNKP's bodily behavior, advancing DNA repair-targeting therapies. Regulatory compliance alongside scientific insight is emphasized as essential components of this endeavor.